Shifting Paradigms: Imidocarb dipropionate as an alternative chemotherapeutic strategy for Trypanosoma evansi infection in animals.

Shifting Paradigms: Imidocarb dipropionate as an alternative chemotherapeutic strategy for Trypanosoma evansi infection in animals.

Overview of Research

• This study evaluates the efficacy and safety of Imidocarb dipropionate (IDP), a known treatment for babesiosis and anaplasmosis, against Trypanosoma evansi infection, which causes Surra in animals.
• Researchers tested IDP’s ability to inhibit the parasite both in vitro (in cell cultures) and in vivo (in mice), while also assessing its cytotoxicity to host cells.

Background

• Trypanosoma evansi is a protozoan parasite causing Surra, a disease affecting various animals with significant economic impact.
• Current treatments have limitations, so there is a need for alternative chemotherapeutic agents.
• Imidocarb dipropionate (IDP) is an aromatic diamidine compound clinically used to treat babesiosis and anaplasmosis, which are other protozoan diseases.

In Vitro Experiments

• The researchers tested the inhibitory concentration (IC) of IDP required to affect T. evansi growth and the cytotoxic concentration (toxicity) on equine peripheral blood mononuclear cells (PBMCs) and Vero cells (a kidney epithelial cell line).
• Findings showed:
  • The IC of IDP against T. evansi was 2.73 µM, indicating effective parasite inhibition at a relatively low concentration.
  • The cytotoxic concentration was much higher—32.66 µM for PBMCs and 80.70 µM for Vero cells—showing a good safety margin between effective doses and toxic doses to host cells.

Gene Expression Analysis

• IDP treatment led to significant downregulation of T. evansi genes associated with:
  • Cell division – slowing the multiplication of the parasite.
  • Glycolysis – interfering with the parasite’s energy metabolism.
  • Nucleic acid synthesis – reducing parasite replication and repair processes.
  • Immune evasion strategies – potentially making the parasite more vulnerable to host immune responses.
  • Redox homeostasis – disrupting the parasite’s oxidative balance, which may increase susceptibility to damage.

In Vivo Experiments in Mice

• Mice infected with T. evansi were treated with IDP at a dose of 20 mg/kg body weight, administered twice intraperitoneally, 72 hours apart.
• Key results included:
  • Prolonged survival of infected mice by 20 days compared to untreated controls.
  • This demonstrates that IDP has significant anti-trypanosomal activity in a living host context.

Safety and Toxicity Observations

• Hematological (blood), biochemical (organ function), and histopathological (tissue structure) analyses were performed to assess adverse effects.
• At four times the therapeutic dosage:
  • Effects on kidney and liver tissues were observed, suggesting potential toxicity at high doses.
  • This indicates a need for careful dosing to avoid organ damage.

Conclusions and Future Recommendations

• IDP shows promise as an alternative chemotherapeutic agent for treating T. evansi infections, with effective parasite inhibition and a reasonable safety margin in vitro.
• In vivo mice studies confirm its activity in prolonging survival but caution due to potential organ toxicity at elevated doses.
• The authors recommend further clinical trials on higher-order animals to establish safety and efficacy before IDP can be widely recommended for treating Surra in clinical veterinary practice.